We have assembled a preeminent team of vaccinologists and vaccine developers at Vaxcyte to harness the Xpress CF technology to create best-in-class vaccines to prevent deadly infectious diseases. Collectively they have invented and/or developed most of the blockbuster vaccines available today, including vaccines to prevent pneumococcus (Prevnar 13® & Synflorix®), human papilloma virus (Gardasil® & Cervarix®), rotavirus (Rotashield® & Rotateq®), herpes zoster (Shingrix® & Zostavax®), measles, mumps, rubella and varicella virus (Proquad®), meningococcus (Menjugate®), dengue virus (Dengvaxia®), Japanese encephalitis (ChimeriVax-JE®), West Nile virus (Prevenile®), yellow fever (Arilvax®), and smallpox, among others.

Jeffrey Almond, PhD

Dr. Almond is Visiting Professor of Microbiology at the William Dunn School of Pathology, University of Oxford and is an Oxford Martin Fellow with the Oxford Martin Programme on Vaccines.  Before that, he was Vice President and Head of Discovery Research and External R&D at Sanofi Pasteur. His scientific contributions include the first demonstration that a single gene can determine the host range of influenza virus – a finding highly relevant to understanding evolution of new pandemic strains; completion of the genetic map of an avian influenza virus, and the first detailed description of the proteins of Influenza B virus. He has also made major contributions to our understanding of poliovirus and its vaccines. In 1985 as a young academic, Dr. Almond won the Fleming Award for outstanding contribution to microbiological research by a young microbiologist in the UK, and the pace and extent of his contributions have not diminished. In his previous role at Sanofi Pasteur, he was responsible for the scientific rationale underpinning approximately 30 vaccine projects covering viruses, bacteria, and eukaryotic parasites. He is an elected Fellow of the American Academy of Microbiology and in 1999 was awarded the Ivanovsky Medal for “Contributions to the Development of Virology” by The Scientific Council of Virology of Russian Academy of Medical Sciences. He is a Fellow of the UK Academy of Medical Sciences and has served on numerous scientific committees in the UK and beyond, including the governing body of the Medical Research Council.

Emmanuel Hanon, PhD, DVM

Dr. Hanon is a healthcare veteran and the Global Head of R&D for Viome, a precision medicine company focused on the prevention, treatment or even cure of chronic disorders. Previously, Dr. Hanon spent 20 years at GlaxoSmithKline (GSK) in R&D roles of increasing responsibility, most recently serving as Senior Vice President, Head of Vaccine R&D and a member of GSK’s Vaccine Executive Team. In this role, he oversaw more than 3,500 employees across 50 countries dedicated to the discovery, development and management activities for GSK’s vaccine efforts. Additionally, Dr. Hanon was responsible for the shared science and technology platforms supporting the entire vaccine business, managing technical development, clinical immunology and preclinical stages of vaccine development. While at GSK, he contributed to the innovation of many vaccines targeting human papilloma virus, malaria, tuberculosis, seasonal and pandemic influenza, shingles, meningitis and RSV.

Dr. Hanon has a Ph.D. in Immunology, Virology, and Vaccinology and a Doctorate in Veterinary Medicine from the University of Liège. He completed his Postdoc in Microbiology and Immunology at Imperial College London.

Tony Ford-Hutchinson, PhD

Dr. Ford-Hutchinson was either head of Vaccine R&D at Merck or responsible for Vaccine Research during which time four important vaccines were discovered and developed: Gardasil®, Zostavax®, Proquad® and Rotateq®. His career at Merck started at Merck Frosst Canada where he spent 17 years moving from Director of Pharmacology to SVP and Site Head. During his time in Canada, the laboratories there developed multiple approved products, including Singulair®, for the treatment of adult and pediatric asthma and allergic rhinitis, and selective COX-2 inhibitors for the treatment of osteoarthritis and pain, becoming the most productive discovery unit within Merck. In 1998, Dr. Hutchinson moved to Pennsylvania to head the basic research efforts worldwide. As an EVP, he became responsible for franchise strategies in multiple disease areas, including Vaccines and Infectious Diseases. He also served as the Chairman of the Board, Hilleman Laboratories, a JV between Merck and the Wellcome Trust with vaccine development laboratories in New Delhi, India.  After 32 years at Merck, he retired in 2012 and has subsequently served on several biotech boards and SABs, including Okairos AG, a vaccine platform company based around viral vectors (acquired by GlaxoSmithKline), Ligocyte Pharmaceuticals, a company developing a vaccine against norovirus infection (acquired by Takeda Pharmaceuticals), Novira Pharmaceuticals, a small molecule start-up developing anti-viral capsid inhibitors (acquired by Johnson & Johnson) and is currently an SAB member of Inovio Pharmaceuticals, a vaccine platform company based around in vivo DNA electroporation and Hookipa AG, a vaccine company based around a novel viral expression system. He is also a member of the Translational Fund Committee at the Wellcome Trust, and a Board Member of SAGE Bionetworks, a not for profit organization aiming to improve the understanding and treatment of human disease through data-driven predictive modeling. Dr. Hutchinson obtained his BSc, MSc, and Ph.D. from the Universities of Birmingham, Warwick, and London.

William Hausdorff, PhD

Dr. Hausdorff has worked on the development, clinical evaluation, registration, implementation and epidemiological assessments of a variety of vaccines over the past 30 years. Since 2018, Dr. Hausdorff has served as the Lead, Public Health Value Propositions for Vaccines at PATH, a global organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises and investors to solve the world’s most pressing health challenges. Prior to joining PATH, he worked for 12 years at GlaxoSmithKline (GSK) Vaccines, eight years at Wyeth Vaccines and was previously at the U.S. Agency for International Development with the Centers for Disease Control and Prevention. In his roles at GSK Vaccines and Wyeth Vaccines, he was involved in the development of Synflorix® and Prevnar 13®, respectively. Dr. Hausdorff performed his post-doctoral work at Duke University after receiving his PhD in Biology from The Johns Hopkins University/National Institutes of Health and his BA in Biology from Carleton College.

Thomas P. Monath, MD

Tom is currently CSO and COO of BioProtection Systems, the infectious disease subsidiary of NewLink Genetics, where he is leading the development of the most advanced Ebola virus vaccine in partnership with Merck. The vaccine was recently shown to provide efficacy after a single dose in Phase 3. He has over 25 years operating experience in the healthcare biotechnology industry and is a former partner in the Pandemic and Biodefense Fund at Kleiner Perkins Caufield & Byers. Before joining NewLink Genetics, Tom was CMO for Hookipa Biotech, Juvaris and Xcellerex. Between 1992 & 2006, he was CSO and Executive Director of Acambis prior to its acquisition by Sanofi Pasteur, where he directed R & D on vaccines against dengue, Japanese encephalitis, West Nile, yellow fever, Clostridium difficile, and smallpox. The dengue vaccine that he invented, Dengvaxia®, was recently approved for human use and is one of four vaccines he developed that are now licensed. He currently serves on the boards of Vaxxinnate, Juvaris, Sentinext, RapidMicro Biosystems, and US Biologic. Before joining the industry, Tom served in the uniformed services of the US Army and US Public Health Service for 24 years prior to retiring as a Colonel. He was Director, Division of Vector-Borne Viral Diseases at the CDC and Prevention and Chief of the Virology Division at USAMRIID. Dr. Monath received his undergraduate degree and MD from Harvard. Tom has received many prestigious awards, including the Nathanial A. Young Award (1984), the Richard M. Taylor Award (1996), the Walter Reed Medal (2002) and the James H. Steele Gold-Headed Cane Award (2015). He has served on numerous government and international committees on infectious diseases, biosecurity, WHO expert committees and the National Vaccines.

Emmanuel Walter, MD, MPH

Dr. Emmanuel Walter is a Professor of Pediatrics at Duke University School of Medicine, the Chief Medical Officer of the Duke Human Vaccine Institute (DHVI) and the Director of the Duke Vaccine and Trials Unit. Dr. Walter provides strategic and operational leadership for clinical research conducted at the DHVI. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities. Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers funded by the National Institute of Allergy and Infectious Diseases (NIAID). Dr. Walter is the Duke Co-Principal Investigator for the NIAID Vaccine and Treatment Evaluation Unit, which conducts clinical trials of vaccines and treatments for infectious diseases. He is also the Duke Principal Investigator for the Centers for Disease Control and Prevention-funded Clinical Immunization Safety Assessment Project, which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Dr. Walter received his MPH from the University of North Carolina – Chapel Hill, MD from the University of Maryland, Baltimore and BS from the University of Notre Dame.